ACTIV Picks Potential COVID-19 Therapeutics To Be Tested In Master Protocol Trials

 
• By Brenda Sandburg

Three host-targeted immune modulators, three anticoagulants, and three to six neutralizing antibodies are to be tested in ACTIV clinical trials, FNIH's David Wholley tells DIA meeting.

Coronavirus COVID-19 medical test vaccine research and development concept. Scientist in laboratory study and analyze scientific sample of Coronavirus antibody to produce drug treatment for COVID-19.
NIH's ACTIV partnership picks therapeutics for COVID-19 cliniical trials

More from Clinical Trials

More from R&D